GRI Bio
7 hedge funds and large institutions have $185K invested in GRI Bio in 2024 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
273% more capital invested
Capital invested by funds: $49.7K → $185K (+$136K)
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
17% more funds holding
Funds holding: 6 → 7 (+1)
0% less ownership
Funds ownership: 0.01% → 0.01% (-0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$46.2K |
| 2 |
VF
Virtu Financial
New York
|
+$21.9K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$14.7K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$11.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$11.7K |
| 2 |
HF
HRT Financial
New York
|
-$5K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$685 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $76.4K | +$14.7K | +43 | +28% |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $63.1K | +$46.2K | +135 | +540% |
|
|
VF
3
Virtu Financial
New York
| $25K | +$21.9K | +64 | New |
|
|
TSS
4
Two Sigma Securities
New York
| $13.1K | +$11.3K | +33 | New |
|
5
BlackRock
New York
| $2.98K | – | – | – |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $2.89K | -$685 | -2 | -22% |
|
|
SS
7
SBI Securities
Tokyo,
Japan
| $1.66K | +$1.37K | +4 | New |
|
8
Bank of America
Charlotte,
North Carolina
| $60 | – | – | – |
|
|
9
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$11.7K | -68 | Closed |
|
|
HF
10
HRT Financial
New York
| – | -$5K | -29 | Closed |
|
GRI Hedge Fund Activity: Q4 2024 in Review
7 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in GRI Bio (GRI) for Q4 2024, worth a combined $185K — up 273% from $49.7K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new GRI positions and 2 closed out — a net gain of 1 holder — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $46.2K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $11.7K sold.
- 7 institutional investors held GRI Bio (GRI) as of Q4 2024, up from 6 in Q3 2024.
- Funds reported $185K of GRI Bio stock for Q4 2024, up 273% quarter-over-quarter.
- 3 funds opened new GRI Bio positions in Q4 2024 and 2 closed out, a net change of +1 holder.
- The largest GRI Bio buyer in Q4 2024 was Geode Capital Management, an estimated $46.2K added.
- The largest GRI Bio seller in Q4 2024 was Susquehanna International Group, an estimated $11.7K sold.
Based on aggregated 13F filings for Q4 2024.